Previous studies have shown that the major effector factors of the Hippo pathway, namely Yes-associated protein (YAP) and transcriptional co-activator PDZ-binding motif (TAZ), play a key role in mediating drug resistance in NSCLC [7]. The gene discussed is YAP1; the disease is non-small cell lung carcinoma.